{"id":32538,"date":"2025-06-24T14:30:57","date_gmt":"2025-06-24T09:00:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32538"},"modified":"2025-06-24T14:31:49","modified_gmt":"2025-06-24T09:01:49","slug":"pharma-news-for-incyte-gilead-archeus","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus","title":{"rendered":"Incyte\u2019s MONJUVI Combo Approved by FDA for Relapsed\/Refractory Follicular Lymphoma; Gilead\u2019s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte\u2019s OPZELURA for Pediatric Atopic Dermatitis (Ages 2\u201311); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals\u2019 HARLIKU Gets First FDA Approval for Alkaptonuria"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a09574973eef\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a09574973eef\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus\/#Incytes_MONJUVI_Combo_Approved_by_FDA_for_RelapsedRefractory_Follicular_Lymphoma\" >Incyte\u2019s MONJUVI Combo Approved by FDA for Relapsed\/Refractory Follicular Lymphoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus\/#Gileads_YEZTUGO_Becomes_First_FDA-Approved_HIV_Prevention_with_6-Month_Protection\" >Gilead\u2019s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus\/#FDA_Reviewing_Incytes_OPZELURA_for_Pediatric_Atopic_Dermatitis_Ages_2%E2%80%9311\" >FDA Reviewing Incyte\u2019s OPZELURA for Pediatric Atopic Dermatitis (Ages 2\u201311)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus\/#Archeus_Technologies_Receives_FDA_Clearance_for_Prostate_Cancer_Therapy_ART-101\" >Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus\/#Cycle_Pharmaceuticals_HARLIKU_Gets_First_FDA_Approval_for_Alkaptonuria\" >Cycle Pharmaceuticals\u2019 HARLIKU Gets First FDA Approval for Alkaptonuria<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-incyte-s-monjuvi-combo-approved-by-fda-for-relapsed-refractory-follicular-lymphoma\"><span class=\"ez-toc-section\" id=\"Incytes_MONJUVI_Combo_Approved_by_FDA_for_RelapsedRefractory_Follicular_Lymphoma\"><\/span>Incyte\u2019s MONJUVI Combo Approved by FDA for Relapsed\/Refractory Follicular Lymphoma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Incyte has announced that the <strong>FDA <\/strong>has approved <strong>MONJUVI (tafasitamab-cxix)<\/strong> in combination with <strong>rituximab and lenalidomide<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights\"><strong>adult patients with relapsed or refractory follicular lymphoma (FL)<\/strong><\/a>. This makes it the <strong>first FDA-approved CD19- and CD20-targeted immunotherapy combination<\/strong> for this patient population. The approval is based on the pivotal Phase III inMIND trial, which showed a significant improvement in progression-free survival (PFS) with the MONJUVI regimen compared to the control arm. Patients receiving the combination therapy had a median PFS of 22.4 months versus 13.9 months in the control arm, marking a hazard ratio of 0.43 (P&lt;0.0001).<\/p>\n\n\n\n<p>The <strong>safety profile<\/strong> of the MONJUVI combination was evaluated in 546 patients. Serious adverse reactions occurred in 33% of patients, with infections being the most common. Grade 3 or 4 laboratory abnormalities included decreased neutrophils and lymphocytes. The approval marks the <strong>second U.S. indication for MONJUVI<\/strong>, which is also approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPatients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without substantial increase in side effects. Based on the data from the inMIND trial, today\u2019s approval brings the first CD19- and CD20-targeted immunotherapy combination and a potential new treatment standard,\u201d said <\/em><strong><em>Herv\u00e9 Hoppenot<\/em><\/strong><em>, CEO of Incyte. \u201cThis second U.S. approval for MONJUVI reinforces our commitment to advancing innovation for the lymphoma community.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA approval of MONJUVI in combination with rituximab and lenalidomide marks a significant advancement, offering a chemotherapy-free option that has demonstrated a meaningful reduction in the risk of disease progression,\u201d said <\/em><strong><em>Dr. Christina Poh<\/em><\/strong><em>, Assistant Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Center.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Follicular lymphoma, the <strong>second most common type of non-Hodgkin lymphoma<\/strong>, accounts for up to <strong>30% of NHL cases<\/strong>. While typically slow-growing, it presents a therapeutic challenge due to frequent relapses and the risk of progression to aggressive forms of lymphoma. <em>\u201cWe are pleased that the FDA has approved tafasitamab, part of a treatment combination offering a new option for patients living with this chronic disease,\u201d<\/em> said <strong>Dr. Mitchell Smith<\/strong>, Chief Medical Officer, Follicular Lymphoma Foundation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gilead-s-yeztugo-becomes-first-fda-approved-hiv-prevention-with-6-month-protection\"><span class=\"ez-toc-section\" id=\"Gileads_YEZTUGO_Becomes_First_FDA-Approved_HIV_Prevention_with_6-Month_Protection\"><\/span>Gilead\u2019s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead Sciences has received <strong>FDA approval for YEZTUGO (lenacapavir)<\/strong>, a long-acting, injectable <strong>HIV-1 capsid inhibitor<\/strong> for <strong>pre-exposure prophylaxis (PrEP)<\/strong> to reduce the risk of <a href=\"https:\/\/www.delveinsight.com\/report-store\/human-immunodeficiency-virus-type-1-hiv-1-market\">sexually acquired HIV in adults and adolescents<\/a> weighing at least 35kg. YEZTUGO becomes the first and only PrEP option in the U.S. that requires just two injections per year. The approval is based on <strong>Phase III PURPOSE 1 and PURPOSE 2 trials<\/strong>, where <strong>\u226599.9% of participants remained HIV negative<\/strong> throughout the study.<\/p>\n\n\n\n<p>Despite the availability of PrEP for over a decade, data from the CDC shows that only 36% of eligible individuals were prescribed PrEP as of 2022. Uptake remains particularly low among women, Black and Latino communities, and people living in the U.S. South, due to barriers such as stigma, adherence issues, and limited awareness. With over 100 new HIV diagnoses each day in the U.S., the approval of a more convenient, long-acting prevention method marks a major advancement in addressing these gaps.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis is a historic day in the decades-long fight against HIV. YEZTUGO is one of the most important scientific breakthroughs of our time\u2026 it could transform HIV prevention,\u201d said <\/em><strong><em>Daniel O\u2019Day<\/em><\/strong><em>, Chairman and CEO, Gilead Sciences. \u201cWith FDA approval and collaboration with our partners, we\u2019re now closer than ever to ending the HIV epidemic.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cYEZTUGO could be the transformative PrEP option we\u2019ve been waiting for\u2014offering the potential to boost PrEP uptake and persistence,\u201d said <\/em><strong><em>Dr. Carlos del Rio<\/em><\/strong><em>, Emory University. \u201cA twice-yearly injection addresses key barriers like adherence and stigma, especially for those on daily oral PrEP regimens.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-reviewing-incyte-s-opzelura-for-pediatric-atopic-dermatitis-ages-2-11\"><span class=\"ez-toc-section\" id=\"FDA_Reviewing_Incytes_OPZELURA_for_Pediatric_Atopic_Dermatitis_Ages_2%E2%80%9311\"><\/span>FDA Reviewing Incyte\u2019s OPZELURA for Pediatric Atopic Dermatitis (Ages 2\u201311)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Incyte announced that the <strong>FDA has extended the review period<\/strong> for its <strong>sNDA of ruxolitinib cream (Opzelura\u00ae)<\/strong> for the treatment of <strong>children aged 2\u201311 with <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-market\"><strong>mild to moderate atopic dermatitis (AD)<\/strong><\/a>. The PDUFA date is now set for September 19, 2025, following the submission of additional chemistry, manufacturing, and controls (CMC) data related to the 0.75% formulation in response to an FDA request.<\/p>\n\n\n\n<p>The sNDA is supported by positive data from the Phase III TRuE-AD3 trial, which met its primary endpoint. A higher percentage of patients using Opzelura achieved Investigator\u2019s Global Assessment-treatment success (IGA-TS) compared to vehicle. A key secondary endpoint\u2014EASI75 at Week 8\u2014was also successfully met. The safety profile remained consistent with no serious infections, cardiovascular events, malignancies, or thromboses reported during the 8-week vehicle-controlled period.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>p\u201cAtopic dermatitis is a chronic, immune-mediated skin condition that can be difficult to manage, particularly in young children,\u201d<\/em> said <strong>Dr. Steven Stein<\/strong>, Chief Medical Officer at Incyte. <em>\u201cWe are confident in Opzelura\u2019s potential as a non-steroidal topical treatment for pediatric AD and are working closely with the FDA to support its review.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The most common treatment-related adverse event observed was <strong>mild application site pain (2.7%)<\/strong>, which did not lead to discontinuation. If approved, <strong>Opzelura could offer a steroid-free treatment alternative<\/strong> for pediatric patients, a significant step forward in addressing unmet needs in younger populations affected by eczema.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-archeus-technologies-receives-fda-clearance-for-prostate-cancer-therapy-art-101\"><span class=\"ez-toc-section\" id=\"Archeus_Technologies_Receives_FDA_Clearance_for_Prostate_Cancer_Therapy_ART-101\"><\/span>Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Archeus Technologies has announced that the<strong> FDA has cleared its Investigational New Drug (IND) application for ART-101<\/strong>, a novel radiopharmaceutical therapy developed for the imaging and treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-resistant-prostate-cancer-mcrpc-market\"><strong>metastatic castration-resistant prostate cancer (mCRPC)<\/strong><\/a>. This approval will allow Archeus to initiate a Phase I clinical trial later in 2025. ART-101 is a PSMA-targeting small molecule with higher tumor uptake and lower off-target accumulation compared to currently approved agents, potentially offering improved efficacy and reduced toxicity.<\/p>\n\n\n\n<p>Developed in collaboration with the University of Wisconsin\u2013Madison and the Wisconsin Alumni Research Foundation, ART-101 is part of Archeus\u2019 growing pipeline of theranostic radiopharmaceuticals. The therapy is designed to deliver alpha particle-emitting isotopes more safely and effectively than existing options, offering a differentiated mechanism for treating PSMA-positive prostate cancer.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThis IND clearance marks an important milestone for Archeus as we prepare to initiate the first of multiple clinical trials set to begin this year,\u201d said <\/em><strong><em>Evan Sengbusch, Ph.D., CEO of Archeus Technologies<\/em><\/strong><em>. \u201cART-101 represents a promising approach to targeting PSMA-positive prostate cancer with the potential to deliver meaningful clinical benefit and reduced side effects for patients.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>In addition to ART-101, Archeus received IND clearance for ARC-706 and its companion diagnostic ARC-166 in October 2024. The company plans to advance both assets as a theranostic pair, especially for use alongside immunotherapies in resistant cancer types. Preclinical results suggest the duo may elicit curative responses and even immune memory in cancers typically unresponsive to immunotherapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cycle-pharmaceuticals-harliku-gets-first-fda-approval-for-alkaptonuria\"><span class=\"ez-toc-section\" id=\"Cycle_Pharmaceuticals_HARLIKU_Gets_First_FDA_Approval_for_Alkaptonuria\"><\/span>Cycle Pharmaceuticals\u2019 HARLIKU Gets First FDA Approval for Alkaptonuria<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Cycle Pharmaceuticals announced that the <strong>FDA has approved HARLIKU (nitisinone) tablets<\/strong> for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alkaptonuria-market\">treatment of <strong>alkaptonuria (AKU)<\/strong><\/a>, an ultra-rare genetic metabolic disorder. HARLIKU, launching in <strong>July 2025<\/strong>, becomes the <strong>first and only FDA-approved therapy<\/strong> to reduce <strong>urine homogentisic acid (HGA)<\/strong> levels in adults with AKU. This approval marks a major milestone for patients suffering from complications like early-onset osteoarthritis, ochronosis, and organ damage, significantly impacting mobility and quality of life.<\/p>\n\n\n\n<p>The approval is based on data from a randomized, no-treatment controlled study of 40 AKU patients conducted by the National Human Genome Research Institute (NHGRI) at the NIH. The study, led by Dr. Wendy J. Introne, MD, demonstrated that long-term treatment with nitisinone significantly improved pain, energy levels, and physical function over three years, as measured by the 36-Item Short-Form Survey.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are deeply grateful for Cycle\u2019s collaboration with Dr. Wendy Introne, Dr. Bill Gahl, and the broader team at the NIH,\u201d said <\/em><strong><em>Steve Fuller, Chief Strategy Officer of Cycle Pharmaceuticals<\/em><\/strong><em>. \u201cWe look forward to making HARLIKU available to U.S. AKU patients as soon as possible and remain committed to supporting the AKU community to the fullest extent of our capabilities.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong><em>Dr. Introne<\/em><\/strong><em> added, \u201cThe approval of HARLIKU is an important advance for the AKU community. Our scientific team has translated decades of research into launching nitisinone as a new treatment option, and we stand hopeful that it can ease the significant burden of AKU.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>With this milestone, HARLIKU becomes Cycle Pharmaceuticals\u2019 eighth commercial product in the U.S., reinforcing the company\u2019s focus on advancing therapies for rare and underserved diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Incyte\u2019s MONJUVI Combo Approved by FDA for Relapsed\/Refractory Follicular Lymphoma Incyte has announced that the FDA has approved MONJUVI (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This makes it the first FDA-approved CD19- and CD20-targeted immunotherapy combination for this patient population. The [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":32539,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[7478,7467,7466,7469,137,204,704,18834,20047,18936,18833,20048,297,18898,16913,18899,299,17856,349,18962,420,639,498,13055],"industry":[17225],"therapeutic_areas":[17237,17231,17228],"class_list":["post-32538","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-atopic-dermatitis","tag-atopic-dermatitis-market","tag-atopic-dermatitis-pipeline","tag-atopic-dermatitis-treatment-market","tag-cancer","tag-delveinsight","tag-fda","tag-follicular-lymphoma","tag-follicular-lymphoma-clinical-trials","tag-follicular-lymphoma-highlights","tag-follicular-lymphoma-market","tag-follicular-lymphoma-treatment","tag-hiv","tag-hiv-drugs","tag-hiv-infection-market","tag-hiv-market","tag-hiv-1","tag-human-immunodeficiency-virus-infection","tag-latest-pharma-news","tag-metastatic-castration-resistant-prostate-cancer","tag-news","tag-pharma-news","tag-prostate-cancer","tag-prostate-cancer-market","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Incyte, Gilead, Archeus<\/title>\n<meta name=\"description\" content=\"Incyte\u2019s MONJUVI; Gilead\u2019s First FDA-Approved YEZTUGO; Incyte\u2019s OPZELURA, Archeus\u2019 ART-101; Cycle\u2019s HARLIKU\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Incyte, Gilead, Archeus\" \/>\n<meta property=\"og:description\" content=\"Incyte\u2019s MONJUVI; Gilead\u2019s First FDA-Approved YEZTUGO; Incyte\u2019s OPZELURA, Archeus\u2019 ART-101; Cycle\u2019s HARLIKU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T09:00:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T09:01:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/24143035\/pharma-news-for-incyte-gilead-archeus.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Incyte, Gilead, Archeus","description":"Incyte\u2019s MONJUVI; Gilead\u2019s First FDA-Approved YEZTUGO; Incyte\u2019s OPZELURA, Archeus\u2019 ART-101; Cycle\u2019s HARLIKU","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Incyte, Gilead, Archeus","og_description":"Incyte\u2019s MONJUVI; Gilead\u2019s First FDA-Approved YEZTUGO; Incyte\u2019s OPZELURA, Archeus\u2019 ART-101; Cycle\u2019s HARLIKU","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-06-24T09:00:57+00:00","article_modified_time":"2025-06-24T09:01:49+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/24143035\/pharma-news-for-incyte-gilead-archeus.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus","name":"Pharma News | Incyte, Gilead, Archeus","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/24143035\/pharma-news-for-incyte-gilead-archeus.png","datePublished":"2025-06-24T09:00:57+00:00","dateModified":"2025-06-24T09:01:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Incyte\u2019s MONJUVI; Gilead\u2019s First FDA-Approved YEZTUGO; Incyte\u2019s OPZELURA, Archeus\u2019 ART-101; Cycle\u2019s HARLIKU","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-incyte-gilead-archeus#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/24143035\/pharma-news-for-incyte-gilead-archeus.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/24143035\/pharma-news-for-incyte-gilead-archeus.png","width":466,"height":284,"caption":"pharma-news-for-incyte-gilead-archeus"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/06\/24143035\/pharma-news-for-incyte-gilead-archeus-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis Treatment Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Clinical Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Highlights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV infection market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV-1<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Human Immunodeficiency Virus Infection<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">metastatic castration-resistant prostate cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Atopic dermatitis<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis Market<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis pipeline<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis Treatment Market<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Clinical Trials<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Highlights<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Treatment<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">HIV Drugs<\/span>","<span class=\"advgb-post-tax-term\">HIV infection market<\/span>","<span class=\"advgb-post-tax-term\">HIV Market<\/span>","<span class=\"advgb-post-tax-term\">HIV-1<\/span>","<span class=\"advgb-post-tax-term\">Human Immunodeficiency Virus Infection<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">metastatic castration-resistant prostate cancer<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 11 months ago"},"absolute_dates":{"created":"Posted on Jun 24, 2025","modified":"Updated on Jun 24, 2025"},"absolute_dates_time":{"created":"Posted on Jun 24, 2025 2:30 pm","modified":"Updated on Jun 24, 2025 2:31 pm"},"featured_img_caption":"pharma-news-for-incyte-gilead-archeus\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32538"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32538\/revisions"}],"predecessor-version":[{"id":32540,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32538\/revisions\/32540"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32539"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32538"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32538"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32538"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32538"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}